GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

TNXP · Mar 31, 2026

Tonix Pharmaceuticals Holding Corp.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001999371-26-010486General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

24.60% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-615.27% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

183.16% · CORE · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

77.06% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-603.91% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

264.80% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

28.64% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History7 statesHistory building

Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/6 normalizedLevel 3 Jun 30, 20250/6 normalizedLevel 3 Sep 30, 20250/6 normalizedLevel 3 Dec 31, 20250/7 normalizedLevel 3 Mar 31, 20260/7 normalizedLevel 3 Jun 30, 20260/7 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Decreased

Previous: 25.70%
Current: 24.60%
Delta: -1.10%

Cash Generation Increased

Previous: -761.76%
Current: -615.27%
Delta: 146.49%

Growth Increased

Previous: 29.85%
Current: 183.16%
Delta: 153.31%

Margin Increased

Previous: 49.34%
Current: 77.06%
Delta: 27.72%

Profitability Increased

Previous: -959.05%
Current: -603.91%
Delta: 355.14%

R And D Intensity Decreased

Previous: 339.41%
Current: 264.80%
Delta: -74.61%

Sbc Intensity Decreased

Previous: 45.91%
Current: 28.64%
Delta: -17.26%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Has State · Tonix Pharmaceuticals Holding Corp. →Transitioned To · TNXP Fundamental State →Transitioned To · TNXP CAPEX_INTENSITY_DECREASED →Transitioned To · TNXP CASH_GENERATION_INCREASED →Transitioned To · TNXP GROWTH_INCREASED →Transitioned To · TNXP MARGIN_INCREASED →Transitioned To · TNXP PROFITABILITY_INCREASED →Transitioned To · TNXP R_AND_D_INTENSITY_DECREASED →Transitioned To · TNXP SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.